Skip to main content
 

Return of the Whoop!

The Resurgence of Pertussis

By Lynn B. DeSanto

Return of the Whoop!


 

Abstract

This interrupted case study outlines the history of pertussis or whooping cough, a disease that in the early 1900s claimed the lives of more people than diphtheria, scarlet fever, and measles combined. Whooping cough continued to afflict and kill a large number of children until well into the 1930s when Pearl Kendrick and Grace Eldering developed a vaccine that by the 1960s reduced the rate of incidence to 5% of what it was in 1934. But the disease was not eradicated, and by 2013 the number of cases was triple the number of the 1980s. Why the resurgence? To answer that question, students will begin by learning about the biochemical and pathogenic effects of the causative agent, Bordetella pertussis. They will then differentiate the original cellular vaccine from the present day acellular version and consider the cultural, economic and epidemiological effects of making the switch. Originally developed for a microbiology course, this case could also be adapted for a general biology or epidemiology course.

   

Date Posted

03/28/2014

Overview

Objectives

  • Explain the morphology, pathogenicity, growth requirements, and treatment of Bordetella pertussis.
  • Differentiate between the cellular vaccine created by Pearl Kendrick and the present day acellular vaccine.
  • Evaluate the pros and cons of following a vaccination schedule and the consequences to society.

Keywords

Whooping cough; pertussis; Bordetella pertussis; vaccine; vaccination; infectious disease; Pearl Kendrick; Grace Eldering

  

Subject Headings

Biology (General)
Epidemiology
Medicine (General)
Microbiology
Public Health

EDUCATIONAL LEVEL

Undergraduate lower division, Undergraduate upper division

  

FORMAT

PDF

   

TOPICAL AREAS

Ethics, History of science, Regulatory issues, Social justice issues, Women in science

   

LANGUAGE

English

   

TYPE/METHODS

Directed, Discussion, Interrupted, Laboratory

 

 

Asset 2